Familial hypercholesterolemia

Related records

Broader conditions (12)

• Disease
• Disease by developmental or physiological process
• Disease by etiologic mechanism
• Disease of genetic or genomic mechanism
• Familial hyperlipidemia
• Hereditary disease
• Human disease
• Hyperlipidemia
• Hyperlipoproteinemia
• Inborn errors of metabolism
• Inherited lipid metabolism disorder
• Metabolic disease

Narrower conditions (5)

• Homozygous familial hypercholesterolemia
• Hypercholesterolemia due to cholesterol 7alpha-hydroxylase deficiency
• Hypercholesterolemia, autosomal dominant, 3
• Hypercholesterolemia, autosomal dominant, type B
• Hypercholesterolemia, familial, 1

Trials (224)

• 2-Hydroxybenzylamine (2-HOBA) to Reduce HDL Modification and Improve HDL Function in Familial Hypercholesterolemia (FH)
• A 12-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05244)
• A 52-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05245)
• A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-833)
• A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH)
• A Long-term Follow-up Study to Evaluate the Safety and Efficacy of RGX-501
• A Pharmacodynamic Study to Evaluate the Effect of a Fixed Dose Combination Pill on Low Density Lipoprotein (LDL) Cholesterol
• A Pilot Study to Evaluate the Lipid Effects of TRIA-662
• A Prospective Cohort Study on Familial Hypercholesterolemia in Health Examination Population
• a Prospective Pilot Study of Screening Out Rate and Clinical Management of Familial Hypercholesterolemia
• A Real-World Study of Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab
• A Registration Study for Familial Hypercholesterolemia in Taiwan
• A Safety and Efficacy Study of DRL-17822, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Patients With Abnormal Cholesterol Levels
• A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)
• A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids
• A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158)
• A Study of SYH2070 Injection in Participants With Mixed Hyperlipidemia
• A Study of the Efficacy and Safety of Enclitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008)
• A Study of the Safety and Efficacy of Patients With Familial Hypercholesterolaemia Taking Colesevelam as add-on Therapy to Their Existing Medication
• A Study of VERVE-101 in Patients With Familial Hypercholesterolemia and Cardiovascular Disease

Approved drugs (16)

• Alirocumab
• Amlodipine besylate
• Atorvastatin calcium
• Bempedoic acid
• Colesevelam hydrochloride
• Evinacumab
• Evolocumab
• Ezetimibe
• Fluvastatin sodium
• Inclisiran sodium
• Lomitapide mesylate
• Mipomersen sodium
• Pitavastatin calcium
• Pravastatin sodium
• Rosuvastatin calcium
• Simvastatin

Drugs in development (21)

• 2-(aminomethyl)phenol Phase 2
• AEM-28 Phase 2
• Anacetrapib Phase 3
• Atorvastatin Phase 3
• Bococizumab Phase 3
• Cholestyramine Phase 3
• Enlicitide decanoate Phase 2
• Eprotirome Phase 3
• Implitapide Phase 2
• Inclisiran Phase 3
• Laropiprant Phase 3
• Lerodalcibep Phase 3
• Lomitapide Phase 3
• Niacin Phase 3
• Omega-3-acid ethyl esters Phase 3
• Ongericimab Phase 3
• Recaticimab Phase 2
• Resmetirom Phase 2
• Rosuvastatin Phase 3
• Tafolecimab Phase 3

Other linked drugs (1)

• Mipomersen